Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

Phase Ii ◽

Phase Ii Study ◽

Intensive Therapy ◽

First Line ◽

Primary Analysis ◽

469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.580 ◽

2020 ◽

Vol 31 ◽

pp. S440

Author(s):

K. Ding ◽

Y. Liu ◽

J. Chen ◽

J. Ying ◽

Q. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Wild Type ◽

First Line ◽

First Line Treatment ◽

420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.941 ◽

2021 ◽

Vol 32 ◽

pp. S545

Author(s):

K. Ding ◽

Y. Liu ◽

J. Du ◽

Y. Zhu ◽

D. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Multicenter Phase ◽

First Line Treatment ◽

First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study

Cancer Science ◽

10.1111/j.1349-7006.2012.02320.x ◽

2012 ◽

Vol 103 (8) ◽

pp. 1502-1507 ◽

Cited By ~ 7

Author(s):

Yasushi Tsuji ◽

Taroh Satoh ◽

Akihito Tsuji ◽

Kei Muro ◽

Motoki Yoshida ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

First Line ◽

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Cited By ~ 5

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

Cancer Medicine ◽

10.1002/cam4.2826 ◽

2020 ◽

Vol 9 (5) ◽

pp. 1779-1789 ◽

Cited By ~ 2

Author(s):

Akira Ooki ◽

Satoshi Morita ◽

Shigeyoshi Iwamoto ◽

Hiroki Hara ◽

Hiroaki Tanioka ◽

...

Keyword(s):

Colorectal Cancer ◽

Prognostic Factor ◽

Phase Ii ◽

Symptom Burden ◽

First Line ◽

Patient Reported ◽

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

BMC Cancer ◽

10.1186/1471-2407-10-567 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 33

Author(s):

Gemma Bruera ◽

Alessandra Santomaggio ◽

Katia Cannita ◽

Paola Lanfiuti Baldi ◽

Marianna Tudini ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BMC Cancer ◽

10.1186/s12885-019-5753-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

A. Carrato ◽

M. Benavides ◽

B. Massutí ◽

R. Ferreiro-Monteagudo ◽

P. García Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Cooperative Group ◽

Pilot Phase ◽

First Line ◽

Frail Patients

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC)

European Journal of Cancer ◽

10.1016/s0959-8049(01)81582-3 ◽

2001 ◽

Vol 37 ◽

pp. S295-S296 ◽

Cited By ~ 1

Author(s):

J. Salvador ◽

R. Bernabe ◽

M. Bolaños ◽

P. Borrega ◽

M. Valladares ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽